middle.news
Why Mayne Pharma’s $7.40 Scheme Acquisition by Cosette Has Board and Expert Backing
6:19pm on Thursday 15th of May, 2025 AEST
•
Healthcare
Read Story
Why Mayne Pharma’s $7.40 Scheme Acquisition by Cosette Has Board and Expert Backing
6:19pm on Thursday 15th of May, 2025 AEST
Key Points
Proposed $7.40 cash per share scheme of arrangement
37% premium to last undisturbed trading price
Unanimous Mayne Pharma board recommendation
Independent Expert Deloitte confirms fairness and reasonableness
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Mayne Pharma (ASX:MYX)
OPEN ARTICLE